New cell therapy trial hopes to tame chronic eye inflammation
NCT ID NCT07427628
First seen Mar 04, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This early-stage study tests a one-time cell therapy called TRX103 for people with active non-infectious uveitis, a condition causing eye inflammation. Up to 18 adults aged 18-70 will receive the treatment intravenously and be monitored for a year. The main goal is to check safety and side effects, while also tracking vision changes and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-INFECTIOUS UVEITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Byers Eye Institute
Palo Alto, California, 94303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.